|
E-mail this page to a friend!
Senior Citizen Health & Medicine
Male Reluctance to Discuss Bowel, Sexual Problems
Misguides Prostate Cancer Treatment
One third in a study of treatment choices appear to
have received inappropriate therapies
Nov. 26, 2007 The unwillingness of many men to
discuss problems such as urinary, bowel or sexual function with their
physician is suspected as one of the reasons that many are receiving the
wrong therapy for the treatment of their prostate cancer. More than one
third of the men with early prostate cancer that participated in a study
of treatment choices appear to have received inappropriate therapies.
Clinical studies have found no differences in
effectiveness among the three major therapies for the treatment of
prostate cancer, but each brings with it certain risks, such as urinary
incontinence or sexual dysfunction.
Therefore, the best therapy for a
particular patient will depend on the individuals pre-treatment status.
For example, patients with pre-existing bowel
dysfunction should not receive external beam radiation as a first line
of therapy because the treatment inevitably irradiates the adjacent
rectum in addition to the prostate and causes acute and long-term bowel
dysfunction.
Prostate cancer patients experience the same fears
and hard decisions as all cancer patients do, but prostate cancer
treatment directly affects very personal things that most people aren't
comfortable talking about urinary, bowel and sexual function, says
James Talcott, MD, SM, of the Center for Outcomes Research at
Massachusetts General Hospital (MGH) Cancer Center, who led the study.
In this case, however, having that information
matters because the three major treatments available to patients have
different patterns of potential side effects. Knowing if patients
already have problems in these areas should help guide treatment
decisions.
The study will appear in the January 1, 2007 issue
of the journal Cancer and is being released online.
The standard treatment options for early prostate
cancer are external radiation therapy; brachytherapy, in which tiny
radioactive particles are implanted into the prostate gland; and
prostatectomy, surgical removal of the prostate gland. These approaches
have similar levels of effectiveness, but each presents a different risk
of side effects external radiation can lead to bowel dysfunction,
brachytherapy may cause urinary problems, and surgery can damage nerves
involved in sexual function.
For patients who already have problems in these
areas, therapies that could worsen their symptoms are usually not
recommended.
In addition, approaches designed to preserve normal
functions, such as nerve-sparing prostate-removal surgery, would not be
appropriate for patients for whom those functions have already been
lost.
To investigate the frequency of treatment
mismatches, the research team enrolled patients treated for early
prostate cancer at four Boston centers over a six-year period. Study
participants completed a questionnaire before beginning treatment and
subsequent questionnaires at intervals of 3, 12, 24 and 36 months after
they entered the study.
They also gave the researchers who were not
involved in their clinical care permission to review their medical
records. The questionnaires were designed to assess urinary incontinence
and other urinary problems, along with bowel and sexual dysfunction.
Participants were also asked to assess their level of distress with any
symptoms they experienced.
Of the almost 440 patients who completed the entire
study, 389 or 89 percent reported having some level of urinary, bowel or
sexual problem before beginning treatment. Those participants were
classified into four groups.
● Group 1 was patients with serious symptoms in a single area, for
whom decisions would be expected to be the most straightforward.
● Group 2 had less serious symptoms that would count against a single
treatment option.
● Group 3 had problems in several areas but still had one potentially
appropriate treatment.
● Group 4 included those patients with significant dysfunction in all
three areas, for whom none of the treatment options would be
recommended.
The study results showed similar levels of
treatment mismatches in all groups 34 percent in Group 1, 37 percent
in Group 2, and 40 percent in Group 3. Among Group 4 patients those
with dysfunction in all three areas only 5 percent chose watchful
waiting, a strategy in which they receive no treatment but are followed
closely by their medical team.
Since patients take many considerations into
account when choosing therapies, the surveys asked about several factors
that might affect those decisions, none of which could account for the
mismatched choices. As expected, patients reporting pre-existing
conditions were more likely to have problems after treatment if they had
received a mismatched treatment.
It could be that treatment choices are determined
by factors other than those we asked about, or patients may decide to go
ahead with mismatched treatments for their own reasons, knowing the
risks, Talcott says.
But it also could be that the open, frank
conversations patients should have with their doctors arent taking
place or that doctors arent making it clear to patients why they should
be forthright about urinary, bowel or sexual problems they are having.
He and his colleagues theorize that patients may be
more open about addressing sensitive topics on a questionnaire than they
are in conversation and suggest that factoring such a questionnaire into
treatment decisions could reduce mismatches, a strategy they hope to
study in the future.
The authors conclude that their observations raise
concerns about physician-patient communication. Similar situations may
also exist for other types of cancer, producing unsuspecting barriers
to patient-centered choices of treatment, palliative care and hospice.
The American Cancer Society estimates that more
than 218,000 American men are diagnosed with prostate cancer and more
than 27,000 die from the disease each year.
Editor's Notes:
First author of the Cancer study is Ronald Chen,
MD, of the MGH Cancer Center; the other co-authors are Jack Clark, MD,
Boston University School of Public Health, and Judith Manola, MS,
Dana-Farber Cancer Institute. The study was supported by a grant from
the Agency for Healthcare Research and Quality.
Massachusetts General Hospital, established in
1811, is the original and largest teaching hospital of Harvard Medical
School. The MGH conducts the largest hospital-based research program in
the United States, with an annual research budget of more than $500
million and major research centers in AIDS, cardiovascular research,
cancer, computational and integrative biology, cutaneous biology, human
genetics, medical imaging, neurodegenerative disorders, regenerative
medicine, systems biology, transplantation biology and photomedicine.
Article: Treatment Mismatch In Early Prostate
Cancer: Do Treatment Choices Take Patient Quality of Life Into Account?
Ronald C. Chen, Jack A. Clark, Judith Manola, and James A. Talcott,
CANCER; Published Online: November 26, 2007 (DOI: 10.1002/cncr.23138);
Print Issue Date: January 1, 2008.
Links to more SeniorJournal.com reports on
Prostate Cancer:
Cancer Cells Zapped by Electrical Impulses with Invention by Engineers
Clinical trials come next for test on prostate cancer victims
July 6, 2007
Researchers Say They
Have Found a Better Test for Prostate Cancer?
April 26, 2007
Proteins from Inflammation are 'Smoking Gun' in Spread of Prostate
Cancer
March 19, 2007
Obesity and
Prostate Cancer a Deadly Combination, Study Finds
March 15, 2007
Seniors May Increase Risk of Heart Disease from Prostate Cancer
Treatment
Feb. 26, 2007
Prostate Cancer
Patients Have High Survival Rates with Seed Implants
January 31, 2007
Radiation Therapy
Combo Cures Prostate Cancer Long-Term
January 4, 2007
Lack
of Sons Puts Men at Higher Risk for Prostate Cancer Says New Study
January 3, 2007
Elderly Men
Survive Prostate Cancer 'Significantly' Longer if Treated
December 22, 2006
Octogenarians Not Too Old for Cancer Surgery, Say Mayo Clinic
Researchers
November 27, 2006
Prostate
Cancer Studies Find Benefit to Radiation, No Harm in Testosterone
Replacement in Older Men
November 14, 2006
Prostate
Cancer Cells Killed by Protein Made by the Cancer
November 10, 2006
Researchers
Urge New Approach to Prostate Cancer Screening with Early PSA Base
November 1, 2006
Prostate Cancer Appears Cured in 89 Percent of Men Treated with IMRT
September 27, 2006
PSA of
Prostate Cancer Victims Can Predict How Long They Will Survive
August 25, 2006
Large Study Finds Some Prostate Cancer Patients
Possibly Overtreated
August 15, 2006
Plant-Based Diet with Stress Reduction Slows
Progression of Prostate Cancer
August 15, 2006 - Also in this news report you will find links
to more associations between prostate cancer and nutrition and
supplements.
Prostate Cancer Cells Killed by RNA-Based Drug
August 10, 2006
Men Found with Prostate Cancer Rush to Judgment on
Treatment
June 26, 2006
Potential of Prostate Cancer Spread Detected Early
by New Test
June 21, 2006
Click to More Senior News on the
Front Page
Copyright: SeniorJournal.com |